Stock Message Boards
ETF Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards Portfolio Channel


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
AMGN Description — Amgen Inc

Amgen is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. Co.'s pipeline includes Evolocumab (AMG 145) for dyslipidemia, Ivabradine for chronic heart failure and stable angina in patients with elevated heart rates, Talimogene Laherparepvec for melanoma, and Trebananib for ovarian cancer. Co. markets its principal products primarily in the U.S. in cancer care, inflammation, nephrology and bone disease. Co. markets pegfilgrastim, granulocyte colony-stimulating factor, darbepoetin alfa, recombinant human erythropoietin and romiplostim under the brand names Neulasta®, NEUPOGEN®/GRANULOKINE®, Aranesp®, EPOGEN® and Nplate®, respectively.

Company Name:  Amgen Inc
Website:  www.amgen.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding AMGN:  89
Total Market Value Held by ETFs:  $5,464,843,194.01
Total Market Capitalization:  $120,803,000,000
% of Market Cap. Held by ETFs:  4.52%
 ETF   AMGN Weight   AMGN Amount 
 SPY   0.64%   $1,226,180,887         
 QQQ   2.39%   $974,056,615         
 XLV   4.25%   $565,445,339         
 IBB   6.98%   $549,601,573         
 IVV   0.64%   $451,269,286         
 IWF   1.01%   $294,540,706         
 VUG   1.33%   $250,311,269         
 IVW   1.21%   $157,825,330         
 IYH   4.04%   $92,687,332         
 PJP   4.92%   $92,126,478         
List of all 89 ETFs holding AMGN »
10 ETFs With Stocks That Insiders Are Buying
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game
Quotes delayed 20 minutes

Buy (2.91 out of 4)
39th percentile
(ranked lower than approx. 61% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite


PARTNER NEWS:

Thu, Mar 5, 9:10 AM, Zacks
Stock Market News for March 05, 2015 - Market News
Markets ended in the red for the second consecutive day, handing the Dow and S&P 500 their worst closing levels since Feb 19

Wed, Mar 4, 10:35 AM, Zacks
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.

ETFs Holding AMGN | Amgen Inc | ETF Channel | www.ETFChannel.com | Copyright © 2009 - 2015, All Rights Reserved

Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; ETF data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.